Apr 18 |
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
|
Apr 17 |
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
|
Apr 8 |
Poseida Therapeutics files to sell 8.33M shares of common stock by holders
|
Apr 8 |
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
|
Mar 26 |
Poseida Therapeutics appoints Syed Rizvi as Chief Medical Officer
|
Mar 25 |
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
|
Mar 19 |
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
|
Mar 17 |
Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
|
Mar 13 |
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
|
Mar 13 |
Poseida spikes after FDA orphan status for CAR-T therapy
|